JP2019529560A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529560A5
JP2019529560A5 JP2019537047A JP2019537047A JP2019529560A5 JP 2019529560 A5 JP2019529560 A5 JP 2019529560A5 JP 2019537047 A JP2019537047 A JP 2019537047A JP 2019537047 A JP2019537047 A JP 2019537047A JP 2019529560 A5 JP2019529560 A5 JP 2019529560A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
inhibitor
patient
csa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019537047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529560A (ja
JP7164530B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/052772 external-priority patent/WO2018057776A1/en
Publication of JP2019529560A publication Critical patent/JP2019529560A/ja
Publication of JP2019529560A5 publication Critical patent/JP2019529560A5/ja
Priority to JP2022128592A priority Critical patent/JP2022160685A/ja
Application granted granted Critical
Publication of JP7164530B2 publication Critical patent/JP7164530B2/ja
Priority to JP2024153668A priority patent/JP2024174962A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019537047A 2016-09-22 2017-09-21 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法 Active JP7164530B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022128592A JP2022160685A (ja) 2016-09-22 2022-08-12 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
JP2024153668A JP2024174962A (ja) 2016-09-22 2024-09-06 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201662397988P 2016-09-22 2016-09-22
US62/397,988 2016-09-22
US201762442083P 2017-01-04 2017-01-04
US62/442,083 2017-01-04
US201762443819P 2017-01-09 2017-01-09
US62/443,819 2017-01-09
US201762445774P 2017-01-13 2017-01-13
US62/445,774 2017-01-13
US201762519896P 2017-06-15 2017-06-15
US62/519,896 2017-06-15
EP17306081.5 2017-08-18
EP17306081 2017-08-18
PCT/US2017/052772 WO2018057776A1 (en) 2016-09-22 2017-09-21 Methods for treating severe atopic dermatitis by administering an il-4r inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022128592A Division JP2022160685A (ja) 2016-09-22 2022-08-12 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法

Publications (3)

Publication Number Publication Date
JP2019529560A JP2019529560A (ja) 2019-10-17
JP2019529560A5 true JP2019529560A5 (enExample) 2020-10-22
JP7164530B2 JP7164530B2 (ja) 2022-11-01

Family

ID=59974890

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019537047A Active JP7164530B2 (ja) 2016-09-22 2017-09-21 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
JP2022128592A Pending JP2022160685A (ja) 2016-09-22 2022-08-12 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
JP2024153668A Pending JP2024174962A (ja) 2016-09-22 2024-09-06 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022128592A Pending JP2022160685A (ja) 2016-09-22 2022-08-12 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
JP2024153668A Pending JP2024174962A (ja) 2016-09-22 2024-09-06 Il-4r阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法

Country Status (13)

Country Link
US (1) US20220110999A1 (enExample)
EP (2) EP3515465B1 (enExample)
JP (3) JP7164530B2 (enExample)
KR (3) KR20190053250A (enExample)
CN (2) CN118203659A (enExample)
AU (2) AU2017332732B2 (enExample)
CA (1) CA3037499A1 (enExample)
ES (1) ES2974376T3 (enExample)
HU (1) HUE066662T2 (enExample)
IL (2) IL310371A (enExample)
MX (3) MX2019003235A (enExample)
PL (1) PL3515465T3 (enExample)
RU (1) RU2759630C2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN118286417A (zh) 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
PT3110848T (pt) 2014-09-24 2024-03-05 Regeneron Pharma Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r
KR102872485B1 (ko) 2016-09-01 2025-10-20 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
CN111494626B (zh) * 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
JP7736667B2 (ja) 2019-08-05 2025-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Il-4rアンタゴニストを投与することによるアトピー性皮膚炎の治療方法
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
KR20230084166A (ko) * 2020-10-09 2023-06-12 쿄와 기린 가부시키가이샤 Ox40 관련 질환을 치료하는 방법
EP4277929A1 (en) * 2021-01-14 2023-11-22 Translate Bio, Inc. Methods and compositions for delivering mrna coded antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
WO2002055101A2 (en) * 2000-12-21 2002-07-18 Inhale Therapeutic Syst Storage stable powder compositions of interleukin-4 receptor
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
CN118286417A (zh) * 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
TWI634900B (zh) * 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r

Similar Documents

Publication Publication Date Title
JP2025172841A5 (enExample)
JP2022543612A5 (enExample)
RU2019111921A (ru) Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
JP2022160685A5 (enExample)
JP2021523188A5 (enExample)
CN106062000B (zh) 通过施用il-4r拮抗剂治疗皮肤感染的方法
RU2016136364A (ru) Способы лечения или предупреждения астмы посредством введения антагониста il-4r
HRP20181227T1 (hr) Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r
JP2023520676A5 (enExample)
RU2019103943A (ru) Применение антагонистов il-13 для лечения атопического дерматита
KR20210010518A (ko) Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법
JP2024174962A5 (enExample)
JP2017507139A5 (enExample)
JP2016523863A5 (enExample)
JP2017512193A5 (enExample)
EP3487881B1 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
JP2017511316A5 (enExample)
Choy et al. Mepolizumab (Nucala) for severe eosinophilic asthma
JP2024530954A5 (enExample)
TW202045537A (zh) 化膿性汗腺炎的治療
AU2023265133A1 (en) Il-13 antibodies for the treatment of atopic dermatitis
JP2022513029A5 (enExample)
JP2025501239A5 (enExample)
Rommer et al. Repurposing multiple sclerosis drugs: a review of studies in neurological and psychiatric conditions
JP2019535716A5 (enExample)